Related references
Note: Only part of the references are listed.Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States
Bruce K. Birmingham et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism
Y. Tomita et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients
Hon-Kit Lee et al.
PHARMACOGENOMICS (2013)
Systemic Exposure to Atorvastatin Between Asian and Caucasian Subjects: A Combined Analysis of 22 Studies
Kuan Gandelman et al.
AMERICAN JOURNAL OF THERAPEUTICS (2012)
Understanding the Critical Disposition Pathways of Statins to Assess Drug-Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1
R. Elsby et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers
Alicia J. Allred et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Postmenopausal hormone therapy for disease prevention: Have we learned any lessons from the past?
J. E. Rossouw
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia
Tsang-Bin Tzeng et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin
Satoshi Kitamura et al.
DRUG METABOLISM AND DISPOSITION (2008)
Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans
J. H. Choi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
M. K. Pasanen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: A randomized, open-label, three-way crossover study
Yunxia Li et al.
CLINICAL THERAPEUTICS (2007)
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS trial)
Prakash C. Deedwania et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers
Y. Y. Lau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)
Jun-ren Zhu et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Marja K. Pasanen et al.
PHARMACOGENETICS AND GENOMICS (2006)
Role of BCRP 421C>A polymorphism on rosuvastatin pharynacokinetics in healthy Chinese males
Wei Zhang et al.
CLINICA CHIMICA ACTA (2006)
ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein
LY Huang et al.
DRUG METABOLISM AND DISPOSITION (2006)
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
E Lee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers
PD Martin et al.
CLINICAL THERAPEUTICS (2003)
Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers
PD Martin et al.
CLINICAL THERAPEUTICS (2003)
Polymorphisms in OATP-C -: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans
RG Tirona et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
